pioglitazone has been researched along with Abdominal Obesity in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome." | 9.16 | Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012) |
| " We evaluated whether the peroxisome proliferator-activated receptor-γ agonist pioglitazone with exercise training improves central and peripheral insulin sensitivity more than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity." | 9.15 | Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. ( Bopp, C; Cade, WT; Hubert, S; Laciny, E; Lassa-Claxton, S; Mondy, KE; Overton, ET; Reeds, DN; Yarasheski, KE, 2011) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 7.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance." | 5.19 | Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014) |
| "We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome." | 5.16 | Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012) |
| " We evaluated whether the peroxisome proliferator-activated receptor-γ agonist pioglitazone with exercise training improves central and peripheral insulin sensitivity more than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity." | 5.15 | Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. ( Bopp, C; Cade, WT; Hubert, S; Laciny, E; Lassa-Claxton, S; Mondy, KE; Overton, ET; Reeds, DN; Yarasheski, KE, 2011) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 3.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Deng, D | 1 |
| Fang, Z | 1 |
| Xu, M | 1 |
| Hu, H | 1 |
| Luo, L | 1 |
| Wang, Y | 1 |
| Yarasheski, KE | 1 |
| Cade, WT | 1 |
| Overton, ET | 1 |
| Mondy, KE | 1 |
| Hubert, S | 1 |
| Laciny, E | 1 |
| Bopp, C | 1 |
| Lassa-Claxton, S | 1 |
| Reeds, DN | 1 |
| Zhang, X | 1 |
| Zhang, R | 1 |
| Raab, S | 1 |
| Zheng, W | 1 |
| Wang, J | 1 |
| Liu, N | 1 |
| Zhu, T | 1 |
| Xue, L | 1 |
| Song, Z | 1 |
| Mao, J | 1 |
| Li, K | 1 |
| Zhang, H | 1 |
| Zhang, Y | 1 |
| Han, C | 1 |
| Ding, Y | 1 |
| Wang, H | 1 |
| Hou, N | 1 |
| Liu, Y | 1 |
| Shang, S | 1 |
| Li, C | 1 |
| Sebokova, E | 1 |
| Cheng, H | 1 |
| Huang, PL | 1 |
| Asadipooya, K | 1 |
| Kalantar-Hormozi, M | 1 |
| Nabipour, I | 1 |
| Kemp, DE | 1 |
| Ismail-Beigi, F | 1 |
| Ganocy, SJ | 1 |
| Conroy, C | 1 |
| Gao, K | 1 |
| Obral, S | 1 |
| Fein, E | 1 |
| Findling, RL | 1 |
| Calabrese, JR | 1 |
| Nakatsuji, H | 1 |
| Kishida, K | 1 |
| Funahashi, T | 1 |
| Shimomura, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exercise and Pioglitazone for HIV-Metabolic Syndromes[NCT00639457] | 44 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Myocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic Syndrome[NCT00656851] | 24 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | cm3 (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 2101 | 2164 |
| Pioglitazone + Exercise Training | 1877 | 1905 |
Percentage of blood volume that is red cells (NCT00639457)
Timeframe: Baseline and Week 16
| Intervention | % red cells (Mean) | |
|---|---|---|
| Baseline Hematocrit | Week 16 Hematocrit | |
| Pioglitazone | 39.9 | 39.6 |
| Pioglitazone + Exercise Training | 40.7 | 39.7 |
(NCT00639457)
Timeframe: Baseline and Week 16
| Intervention | g/L (Mean) | |
|---|---|---|
| Baseline Hemoglobin | Week 16 Hemoglobin | |
| Pioglitazone | 13.8 | 13.7 |
| Pioglitazone + Exercise Training | 13.8 | 13.6 |
ability of insulin to suppress hepatic glucose production = hepatic insulin sensitivity (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | percent suppression (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 32 | 40 |
| Pioglitazone + Exercise Training | 37 | 42 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | percent of water (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 12.1 | 10.7 |
| Pioglitazone + Exercise Training | 8.0 | 5.5 |
Insulin-mediated glucose disposal rate per kg of fat free mass per min (NCT00639457)
Timeframe: Baseline and week16
| Intervention | µmol glucose/kg FFM/min (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 30 | 37 |
| Pioglitazone + Exercise Training | 34 | 48 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| Baseline ALT | Week 16 ALT | Baseline AST | Week 16 AST | |
| Pioglitazone | 38 | 39 | 34 | 30 |
| Pioglitazone + Exercise Training | 34 | 32 | 27 | 27 |
E/A ratio; ratio of the early (E) to late (A) ventricular filling velocities (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | ratio (Mean) | |
|---|---|---|
| Baseline E/A ratio | Week 16 E/A ratio | |
| Pioglitazone | 1.3 | 1.4 |
| Pioglitazone + Exercise Training | 1.2 | 1.4 |
Diastolic blood pressure; vascular pressure during ventricular relaxation (diastole) (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline DBP | Week 16 DBP | |
| Pioglitazone | 65 | 67 |
| Pioglitazone + Exercise Training | 68 | 61 |
Deceleration time; time from the peak of early diastolic filling to baseline (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | msec (Mean) | |
|---|---|---|
| Baseline DT | Week 16 DT | |
| Pioglitazone | 204 | 193 |
| Pioglitazone + Exercise Training | 214 | 190 |
Time required to empty the left ventricle into the aorta (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | msec (Mean) | |
|---|---|---|
| Baseline LV ejection time | Week 16 LV ejection time | |
| Pioglitazone | 296 | 294 |
| Pioglitazone + Exercise Training | 281 | 305 |
Systolic blood pressure; peak vascular pressure during ventricular contraction (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline SBP | Week 16 SBP | |
| Pioglitazone | 114 | 114 |
| Pioglitazone + Exercise Training | 121 | 114 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | µg/mL (Mean) | |
|---|---|---|
| Baseline serum adiponectin | Week 16 serum adiponectin | |
| Pioglitazone | 4.7 | 7.0 |
| Pioglitazone + Exercise Training | 4.8 | 6.5 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | mM/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline Triglycerides | Week 16 Triglycerides | Baseline Total Cholesterol | Week 16 Total cholesterol | Baseline LDL cholesterol | Week 16 LDL cholesterol | Baseline HDL cholesterol | Week 16 HDL cholesterol | |
| Pioglitazone | 2.3 | 2.5 | 4.9 | 4.6 | 2.8 | 2.5 | 0.99 | 0.98 |
| Pioglitazone + Exercise Training | 2.1 | 1.8 | 4.7 | 4.5 | 2.7 | 2.6 | 1.06 | 1.09 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | cm3 (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 1933 | 1970 |
| Pioglitazone + Exercise Training | 1890 | 1746 |
fasting plasma glucose, insulin concentrations and HOMA-insulin resistance (NCT00656851)
Timeframe: Week 0 and 16
| Intervention | mg/dL µU/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| glucose (mg/dL) wk 0 | glucose wk 16 | insulin (µU/mL) wk 0 | insulin wk 16 | HOMA-IR wk 0 | HOMA-IR wk 16 | |
| Exercise Training | 91.9 | 86.8 | 14.8 | 11.8 | 3.3 | 2.6 |
| Pioglitazone | 102 | 95.3 | 20.5 | 11.4 | 6.1 | 2.8 |
fasting serum triglycerides, LDL-, and HDL-cholesterol concentrations (NCT00656851)
Timeframe: Week 0 and 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| triglycerides wk 0 | triglycerides wk 16 | LDL-cholesterol wk 0 | LDL-cholesterol wk 16 | HDL-cholesterol wk 0 | HDL-cholesterol wk 16 | |
| Exercise Training | 185 | 159 | 112 | 90 | 38.1 | 39.8 |
| Pioglitazone | 199 | 182 | 115 | 97 | 38.9 | 38.8 |
"Echocardiographic quantification of (E/A) early to late diastolic filling velocity. Aria transfer blood to the ventricles in 2 steps:~blood collected in the atria falls into the ventricles when the atrioventricular valves opens. In the left heart, the velocity at which the blood moves during this initial action is called the early or E filling velocity.~residual blood in the atria, is emptied during diastole by atrial contraction. The velocity of the blood during atrial contraction is the A (for atrial) filling velocity. These are expressed as a ratio (E/A). If A exceeds E velocity (ratio <1.0) this is a clinical marker of diastolic dysfunction. This can occur when the left ventricular wall becomes so stiff as to impair proper filling, which can lead to diastolic heart failure." (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | ratio (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 1.4 | 1.5 |
| Pioglitazone | 1.4 | 1.4 |
Echocardiographic quantification of E' wall velocity during systole averaged at the lateral wall and septum (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | cm/sec (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 13.1 | 13.6 |
| Pioglitazone | 12.7 | 12.8 |
Radio-tracer (11C-palmitate) and positron emission tomography quantification of myocardial fatty acid esterification as a % of total fatty acid extraction (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (% of total fatty acid extraction) (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 4 | 7 |
| Pioglitazone | 7 | 4 |
Radio-tracer (11C-palmitate) and positron emission tomography quantification of myocardial fatty acid oxidation rate. (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol palmitate/g heart muscle/min (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 106.3 | 97.5 |
| Pioglitazone | 92.4 | 110.1 |
Radio-tracer (11C-palmitate) and positron emission tomography quantification of myocardial fatty acid utilization rate. The rate at which palmitate exits the blood, enters the muscle cells in the left ventricle, and is metabolized (oxidation, re-esterification). (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol palmitate/g heart muscle/min (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 119.8 | 130.4 |
| Pioglitazone | 119.3 | 129.3 |
Radio-tracer (11C-glucose) and positron emission tomography quantification of myocardial glucose utilization rate. The rate at which glucose exits the blood, enters the muscle cells in the left ventricle, and is metabolized (ATP generation, glycolysis, glycogenolysis, or lactate production). Total glucose utilization rate in the left ventricle of the heart. (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol glucose/g heart muscle/min (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 106.7 | 87.2 |
| Pioglitazone | 109.6 | 109.1 |
Radio-tracer (11C-glucose) and positron emission tomography quantification of myocardial glucose utilization rate per unit of plasma insulin. Total glucose utilization rate in the left ventricle of the heart expressed per unit of the circulating plasma insulin concentration. (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol glucose/g heart muscle/min/µU insu (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 11.9 | 21.7 |
| Pioglitazone | 14.9 | 15.7 |
4 trials available for pioglitazone and Abdominal Obesity
| Article | Year |
|---|---|
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans | 2014 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Pioglitazone reduces central obesity in polycystic ovary syndrome women.
Topics: Adult; Body Mass Index; Body Weight; Female; Hirsutism; Humans; Hypoglycemic Agents; Intra-Abdominal | 2012 |
Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypog | 2012 |
2 other studies available for pioglitazone and Abdominal Obesity
| Article | Year |
|---|---|
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism; | 2011 |
Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity.
Topics: Aged; Biomarkers; Body Mass Index; Calgranulin A; Calgranulin B; Diabetes Mellitus, Type 2; Female; | 2012 |